List of Excipients in Branded Drug METFORMIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	CANDELILLA WAX
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	CELLULOSE ACETATE
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	FERROSOFERRIC OXIDE
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	HYPROMELLOSES
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	MAGNESIUM STEARATE
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	POLYETHYLENE GLYCOL 400

Generic Drugs Containing METFORMIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Eon Labs Inc	metformin hydrochloride	0185-4416	CARBOXYMETHYLCELLULOSE SODIUM
Eon Labs Inc	metformin hydrochloride	0185-4416	CELLULOSE, MICROCRYSTALLINE
Eon Labs Inc	metformin hydrochloride	0185-4416	HYPROMELLOSE
Eon Labs Inc	metformin hydrochloride	0185-4416	MAGNESIUM STEARATE
Eon Labs Inc	metformin hydrochloride	0185-4416	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	metformin	0378-6002	AMMONIA

What are the Most Frequently-Used Excipients in METFORMIN HYDROCHLORIDE?

# Of NDCs	Excipient
56	ACACIA
3	ACETONE
45	ALCOHOL
14	AMMONIA
16	AMMONIO METHACRYLATE COPOLYMER TYPE A
9	AMMONIO METHACRYLATE COPOLYMER TYPE B

Metformin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Metformin hydrochloride is a mature, low-cost generic active pharmaceutical ingredient with limited opportunity in conventional immediate-release tablets. Commercial value is concentrated in differentiated delivery systems, gastrointestinal-tolerability improvements, fixed-dose combinations, pediatric and geriatric dosage forms, and manufacturing platforms that reduce tablet size or improve process efficiency. Core metformin composition patents have largely expired, so competitive advantage depends more on formulation performance, regulatory execution, supply reliability, and device or process know-how than on basic API exclusivity.

What is the commercial position of metformin hydrochloride?

Metformin hydrochloride is the hydrochloride salt of metformin, a biguanide used primarily for glycemic control in type 2 diabetes. Immediate-release and extended-release oral products are approved in the United States and other major markets.

The principal commercial constraints are:

• High generic competition.
• Low unit pricing for immediate-release tablets.
• Large tablet mass at common doses.
• Dose-related gastrointestinal adverse effects.
• Poor patient adherence in some populations.
• Limited protection available for the active ingredient itself.
• Significant competition from newer diabetes therapies, including SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors.

The opportunity is therefore not to commercialize another undifferentiated 500 mg or 1,000 mg immediate-release tablet. The stronger opportunities involve lower pill burden, improved tolerability, once-daily dosing, liquid or sprinkle formats, and combination products.

What excipient problems must a metformin formulation solve?

Metformin hydrochloride has a high daily dose and presents a demanding formulation profile. The active ingredient is highly water soluble, but the dose creates substantial tablet-volume and manufacturability challenges.

High drug loading

A standard daily regimen can require 1,500 mg to 2,000 mg of metformin hydrochloride. Excipients must support adequate hardness, friability, disintegration, dissolution, and content uniformity without producing an excessively large tablet.

Useful excipient functions include:

Formulation need	Relevant excipient categories	Commercial objective
Direct compression	Microcrystalline cellulose, silicified microcrystalline cellulose, coprocessed fillers	Reduce granulation steps and improve throughput
Flow improvement	Colloidal silicon dioxide	Improve die filling and content uniformity
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduce sticking and ejection force
Binding	Povidone, hypromellose, pregelatinized starch	Improve granule and tablet strength
Rapid disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Accelerate tablet breakup
Taste masking	Film coatings, ion-exchange resins, lipid barriers, polymeric coatings	Enable liquids, chewables, and orally disintegrating systems
Extended release	Hypromellose, polyethylene oxide, ethylcellulose, methacrylate polymers	Control drug release over 12 to 24 hours
Moisture protection	Film coatings, desiccant systems, low-moisture packaging	Protect physical stability and appearance

The exact excipient selection must be driven by dissolution, compression, stability, and scale-up data. Metformin formulations can be sensitive to tablet porosity, polymer grade, granulation endpoint, lubricant concentration, and compression force.

Gastrointestinal tolerability

The most commercially relevant performance target is reduction of gastrointestinal symptoms, including diarrhea, nausea, abdominal discomfort, and flatulence. These effects are linked to local exposure in the gastrointestinal tract and are more common with immediate-release administration or rapid dose escalation.

An excipient strategy can address tolerability through:

• Slower drug release.
• More uniform release across the gastrointestinal tract.
• Reduced local concentration peaks.
• Once-daily administration.
• Delayed or controlled release.
• Multiparticulate dosage forms.
• Food-compatible dosing instructions.

A formulation cannot claim improved tolerability solely because it uses a particular excipient. The sponsor must establish the benefit through comparative clinical or pharmacokinetic evidence appropriate to the proposed labeling.

What formulations are protected by metformin patents?

The original metformin molecule and conventional immediate-release tablet concepts are no longer strong sources of exclusivity in major markets. Historical patent activity focused on extended-release matrices, osmotic delivery, controlled-release granules, combination products, and specific manufacturing methods.

Immediate-release tablets

Immediate-release metformin hydrochloride tablets are generally exposed to generic competition. The main barriers are manufacturing economics, FDA approval, bioequivalence, and supply-chain execution rather than composition-of-matter exclusivity.

An excipient supplier can still create commercial value by offering:

• High-functionality direct-compression grades.
• Low-dusting, high-flow excipients.
• Reduced tablet-weight systems.
• Robust formulations across multiple API sources.
• Improved compression at high drug loading.
• Ready-to-use premixes for generic manufacturers.

Extended-release products

Extended-release products have historically provided the strongest commercial differentiation. U.S. products have included Glucophage XR, Fortamet, and Glumetza. Their technologies used different controlled-release approaches, including hydrophilic matrices and osmotic or gastric-retentive concepts.

Historical U.S. patent estates associated with extended-release metformin included:

Product or technology area	Historical protection	Current strategic relevance
Glucophage XR-type extended-release matrix	Product and formulation patents listed in FDA records	Core protection has expired or is no longer a dependable barrier in the U.S.
Fortamet-type osmotic delivery	Osmotic controlled-release patents	Delivery architecture remains technically relevant but requires new, enforceable claims
Glumetza-type gastric-retentive or controlled-release formulation	Product-specific formulation patents	May support formulation know-how, but historical exclusivity is not equivalent to current freedom from competition
Metformin fixed-dose combinations	Combination and method-of-use claims	Depends on the partner active ingredient and jurisdiction

The FDA Orange Book remains the primary U.S. source for current listed patents, expiration dates, and exclusivity codes. Product-specific conclusions should be based on the current listing for the relevant reference product, not on historical patent summaries.[1]

When does metformin lose exclusivity?

Metformin has already lost practical exclusivity for its basic active ingredient and immediate-release tablet products in the United States. Generic products are widely approved.

U.S. regulatory status

Metformin hydrochloride is approved as an oral prescription drug. Immediate-release tablets, extended-release tablets, and oral solutions are represented in U.S. labeling and generic approvals. The reference products and approved generics are identified through FDA Drugs@FDA, the Orange Book, and product labeling databases.[1,2]

The relevant exclusivity structure is:

Exclusivity type	Metformin position
New chemical entity exclusivity	Expired
Basic composition-of-matter protection	Expired
Immediate-release generic competition	Established
Extended-release product protection	Historical, with current status dependent on product-specific listings
Pediatric exclusivity	Not a general current barrier to metformin development
Orphan exclusivity	Not applicable to routine type 2 diabetes use
Biosimilar exclusivity	Not applicable

A new sponsor can pursue an abbreviated new drug application for a qualifying generic product or a 505(b)(2) application when the formulation, dosage form, delivery system, or proposed labeling relies partly on existing findings but requires a distinct regulatory pathway.[3]

How strong is the patent estate for metformin hydrochloride?

The patent estate is weak for conventional metformin and potentially stronger for genuinely differentiated delivery technology.

Patent strength by opportunity

Opportunity	Likely patent strength	Main risk
Conventional 500 mg immediate-release tablet	Low	Price erosion and mature generic competition
Smaller high-load tablet	Moderate	Easy design-around unless supported by process or excipient claims
Once-daily extended-release tablet	Moderate	Crowded prior art and bioequivalence complexity
Osmotic delivery system	Moderate to high if technically distinct	Existing delivery patents and freedom-to-operate exposure
Gastrointestinal-tolerability formulation	Moderate	Clinical benefit must be demonstrated
Oral solution	Low to moderate	Taste masking, stability, and device barriers
Sprinkle or multiparticulate product	Moderate	Dosage-form and release-profile differentiation
Fixed-dose combination	Moderate to high	Combination-specific prior art and partner-product rights
Pediatric formulation	Moderate	Small market and formulation-specific clinical requirements
Manufacturing process	Moderate	Process claims can be difficult to detect and enforce

The strongest patent strategy would combine several claim types:

1. Composition claims covering a defined excipient system.
2. Dissolution-profile claims tied to a reproducible formulation.
3. Process claims covering granulation, coating, or compression.
4. Dosage-form claims covering multiparticulates, sachets, or sprinkle systems.
5. Method-of-use claims directed to improved tolerability, adherence, or dose administration.
6. Packaging or moisture-control claims where stability depends on the package.

A patent that claims only a familiar polymer, such as hypromellose, at a broad concentration range is vulnerable to obviousness and anticipation challenges. More defensible claims would link excipient grades, process conditions, tablet attributes, and dissolution performance.

What excipient strategies offer the best commercial opportunities?

1. High-drug-load direct compression

A high-drug-load direct-compression platform can reduce manufacturing cost and eliminate wet granulation. The commercial proposition is strongest when the formulation:

• Maintains tablet hardness at low compression force.
• Limits sticking and picking.
• Delivers acceptable friability.
• Tolerates API variability.
• Supports multiple dose strengths.
• Uses common compendial excipients.
• Avoids new impurity or stability concerns.

Coprocessed excipients can be attractive because they combine filler, binder, and flow functions. The regulatory advantage is greater when the individual components have established pharmaceutical use and the supplier provides robust quality documentation.

2. Extended-release matrix systems

Hydrophilic matrix systems using hypromellose or polyethylene oxide remain commercially practical. The key technical variables include:

• Polymer viscosity grade.
• Polymer particle size.
• Drug-to-polymer ratio.
• Tablet geometry.
• Compression force.
• Hydration and gel-layer development.
• Food effect.
• Alcohol-dose-dumping risk.

The product must meet dissolution specifications across the intended pH range and demonstrate bioequivalence or clinical comparability under the applicable FDA pathway. A formulation that performs well in a single dissolution medium may fail under fed, fasted, high-alcohol, or agitation-stress conditions.

3. Multiparticulate and sprinkle products

Multiparticulate systems can improve administration for patients who cannot swallow large tablets. Potential formats include:

• Coated pellets.
• Mini-tablets.
• Granules in sachets.
• Capsules that can be opened and sprinkled on soft food.
• Modified-release oral suspensions.

These systems require control of particle-size distribution, coating uniformity, dose recovery, content uniformity, and release after administration with food. Labeling must specify whether the product may be crushed, chewed, dissolved, or mixed with particular foods.

4. Taste-masked liquid metformin

Metformin is intensely bitter. An oral solution or suspension requires more than sweetening. A viable excipient system may use:

• Ion-exchange resins.
• pH adjustment.
• Polymer coating.
• Complexation.
• Flavor systems.
• Viscosity modifiers.
• Preservatives.
• Chelating agents where justified.
• Low-sorption packaging.

The principal commercial targets are pediatric patients, older adults, patients with dysphagia, and care settings that require liquid administration. The main risks are taste persistence, dose-measuring error, microbial stability, precipitation, and limited reimbursement.

FDA’s Inactive Ingredient Database can support initial excipient precedent analysis, but precedent does not eliminate the need to justify concentration, route, dosage form, and patient population.[4]

5. Fixed-dose combinations

Metformin is widely used in combination with other glucose-lowering agents. Commercial opportunities include combinations with:

• DPP-4 inhibitors.
• SGLT2 inhibitors.
• Sulfonylureas.
• Thiazolidinediones.
• Other established diabetes agents.

Combination products can reduce pill burden and support adherence, but the patent estate may be controlled by the partner active ingredient. A formulation sponsor must assess:

• Active-ingredient patent expiration.
• Orange Book-listed patents.
• Drug-drug compatibility.
• Differential release requirements.
• Dose flexibility.
• Bioequivalence design.
• Existing settlement agreements.
• Royalty or licensing obligations.

A metformin excipient platform may have limited value if the second active ingredient remains protected by a strong composition or formulation patent.

What FDA regulatory pathway applies to new metformin formulations?

The pathway depends on whether the product is pharmaceutically equivalent to an approved reference product or has meaningful formulation, dosage-form, or labeling differences.

ANDA pathway

An ANDA is generally appropriate for a generic product that matches the reference product in active ingredient, dosage form, strength, route of administration, and required performance characteristics. The sponsor must address bioequivalence, chemistry, manufacturing, and controls.

505(b)(2) pathway

A 505(b)(2) application may be more appropriate for:

• A novel extended-release system.
• A new oral liquid.
• A new sprinkle product.
• A different dosage form.
• A formulation with a new administration method.
• A product requiring reliance on published literature or FDA findings for part of its approval basis.

The 505(b)(2) route can create a stronger commercial position than a standard ANDA, but it can also trigger patent certification obligations and potential litigation under the Hatch-Waxman framework.[3]

505(j) and Paragraph IV risk

A generic sponsor submitting an ANDA may file a Paragraph IV certification against listed patents it believes are invalid, unenforceable, or not infringed. The reference-product sponsor can file patent litigation within the statutory period, potentially triggering a 30-month stay of approval, subject to statutory exceptions and court action.[5]

For mature metformin products, Paragraph IV risk is most relevant to extended-release formulations, combination products, and any product with current Orange Book-listed patents. A sponsor seeking differentiated excipient protection should expect competitors to assess design-around options rather than challenge only the active ingredient.

What patent litigation and settlement issues affect metformin?

Historical litigation around extended-release metformin products involved Orange Book-listed formulation patents, generic challenges, and commercial settlements. The legal status of each product must be reviewed through current FDA listings, court dockets, and settlement records.

Key diligence issues include:

• Whether the patent is listed for the specific reference product.
• Whether the listed patent covers the proposed dosage form.
• Whether a formulation patent survives reexamination, disclaimer, terminal disclaimer, or post-grant proceedings.
• Whether a settlement restricts launch timing.
• Whether a license is product-specific or applies to a broader formulation platform.
• Whether a settlement includes authorized-generic rights or supply obligations.
• Whether non-U.S. rights were included.

A historical settlement is not evidence that a corresponding patent remains enforceable. Patent expiration, claim construction, prosecution history, and product-specific infringement analysis control.

Which companies are challenging or competing with metformin products?

The immediate-release market includes numerous generic manufacturers, while extended-release competition has involved major generic companies and specialty pharmaceutical firms. The relevant competitive groups include:

• Large generic manufacturers with high-volume tablet manufacturing.
• Contract development and manufacturing organizations.
• Excipient suppliers offering direct-compression or controlled-release platforms.
• Specialty companies developing liquid, sprinkle, or combination products.
• Diabetes companies using metformin in fixed-dose combinations.

Competition is primarily commercial rather than molecule-driven. The lowest-cost manufacturers can compete on price, while differentiated developers must compete on adherence, tolerability, dosing convenience, or access to a protected combination product.

What licensing deals create opportunities around metformin excipients?

Historical commercial arrangements for branded extended-release metformin products demonstrate that delivery technology can have licensing value. Depomed, Santarus, Salix, Valeant, and other companies have been associated with commercialization and rights transactions involving branded gastrointestinal and diabetes products, including metformin-related products.

Current licensing opportunities are more likely to involve:

• Polymer and coating technology.
• Ready-to-use granulation systems.
• Taste-masking platforms.
• Modified-release multiparticulates.
• Pediatric dosage forms.
• Fixed-dose combination development.
• Regional rights for emerging markets.
• Contract manufacturing with technology transfer.

The most valuable licensable asset is usually a development-ready formulation with comparative dissolution, stability, scale-up data, and a credible regulatory pathway. A generic excipient blend without performance data has limited bargaining power.

What geographic markets offer the best metformin opportunities?

United States

The U.S. market has strong regulatory precedent but intense generic competition. Opportunities favor 505(b)(2) products, specialty dosage forms, and fixed-dose combinations where the partner product supports premium pricing.

European Union

The European Union has established metformin use and substantial generic penetration. Commercial differentiation may depend on national reimbursement, pack size, patient administration needs, and local substitution policy. European excipient compliance and pharmacopoeial requirements must be assessed separately from U.S. FDA expectations.[6]

Emerging markets

Emerging markets offer larger opportunities for low-cost manufacturing, combination products, and pediatric or liquid formulations. Risks include price controls, tender procurement, local manufacturing requirements, variable enforcement of intellectual property, and differences in bioequivalence standards.

Japan and other regulated markets

Japan and other regulated markets may offer opportunities for smaller tablets, patient-friendly dosage forms, and locally adapted administration systems. Development must account for country-specific clinical, quality, and excipient requirements.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are process robustness and scale-up, not API synthesis.

Important technical risks include:

• Segregation caused by high API loading.
• Poor flow into large tablet dies.
• Compression defects.
• Sticking and picking.
• Variable granule density.
• Polymer migration or coating defects.
• Dissolution drift after scale-up.
• Stability changes caused by moisture uptake.
• Food-effect variability.
• Alcohol-induced dose dumping.
• Incompatibility between metformin and colorants, flavors, or preservatives.

An excipient supplier can improve defensibility by documenting:

• Excipient particle-size distribution.
• Bulk and tapped density.
• Moisture profile.
• Specific surface area.
• Functional performance by lot.
• Compatibility with multiple metformin API sources.
• Process design space.
• Stability under commercial packaging.
• Scale-up from laboratory to production equipment.

These data can support formulation patents, know-how protection, regulatory filings, and customer retention even where broad composition claims are unavailable.

How does metformin compare with newer diabetes drugs?

Metformin has a weaker patent position but a lower cost base and broad clinical familiarity.

Attribute	Metformin hydrochloride	SGLT2 inhibitors	GLP-1 receptor agonists
Molecule status	Mature generic	Many products historically patent-protected	Many products patent-protected
Typical dosage form	Oral tablet or liquid	Oral tablet	Injectable or oral, depending on product
Excipient opportunity	Modified release, taste masking, combinations	Tablet and solid-dispersion technology	Stabilization, delivery systems, device technology
Price potential	Low for standard tablets	Higher	Higher
Patient burden	GI effects and tablet size	Dosing-specific	Injection or complex oral delivery
Biosimilar relevance	None	None for small molecules	Depends on biological product classification
Main commercial advantage	Low cost and established use	Cardiovascular and renal positioning	Glycemic and weight-management positioning

Metformin remains commercially relevant as a first-line therapy and as the base component of combination treatment. Its commercial value is volume-driven, while newer drugs offer higher revenue per patient but face greater patent and development barriers.

What generic launch scenarios exist for new metformin products?

Scenario 1: Low-cost immediate-release launch

This is the fastest route but has the weakest margin profile. Success requires efficient manufacturing, reliable API supply, and access to pharmacy or institutional channels.

Scenario 2: Extended-release generic

This offers a larger formulation-development opportunity but requires more complex dissolution and bioequivalence work. Market entry timing depends on current patents and exclusivity for the selected reference product.

Scenario 3: 505(b)(2) liquid or sprinkle product

This can support differentiation in dysphagia, pediatric, geriatric, and long-term-care markets. Taste, stability, dosing accuracy, and reimbursement determine commercial viability.

Scenario 4: Fixed-dose combination

This can reduce pill burden and support branded or specialty-generic positioning. The principal risk is exposure to patents covering the companion active ingredient.

Scenario 5: Excipient-enabled platform licensing

A supplier can license a formulation platform to multiple manufacturers. The strongest model combines excipient supply, technical transfer, regulatory support, and field-of-use restrictions.

Key Takeaways

• Conventional immediate-release metformin hydrochloride has limited patent and pricing power.
• The best excipient opportunities involve extended release, high-drug-load compression, taste masking, multiparticulates, pediatric liquids, and fixed-dose combinations.
• Hypromellose, polyethylene oxide, direct-compression fillers, superdisintegrants, coating polymers, ion-exchange resins, and functional coprocessed excipients are commercially relevant.
• New patent value must come from a defined formulation, process, dissolution profile, dosage form, or clinical-use benefit.
• Biosimilar risk is not relevant because metformin is a small-molecule drug.
• FDA Orange Book listings and current product-specific patent records control U.S. exclusivity analysis.
• A 505(b)(2) product may offer greater differentiation than another standard ANDA tablet, but it carries higher development and patent-certification complexity.
• Revenue potential is strongest where formulation differentiation addresses adherence, swallowing difficulty, gastrointestinal tolerability, or combination-product convenience.
• Manufacturing know-how, excipient functionality, stability data, and scale-up reliability can be more valuable than broad patent claims.

FAQs About Metformin Hydrochloride Excipient Strategy

Can metformin hydrochloride be formulated as an orally disintegrating tablet?

Yes, but the high dose and intensely bitter taste create major constraints. An orally disintegrating product would require taste masking, rapid dispersion, acceptable tablet size, and evidence that the dosage form does not compromise dose accuracy or tolerability.

Which excipient is most suitable for metformin extended release?

Hypromellose is a common starting point for hydrophilic matrix systems. Polyethylene oxide, ethylcellulose, and methacrylate polymers may be suitable depending on the target release profile, manufacturing process, and regulatory strategy. No single polymer is optimal for every design.

Is a metformin hydrochloride formulation patentable?

Potentially. Patentability is more credible when the formulation has a non-obvious excipient combination, a reproducible release profile, an unexpected stability or tolerability benefit, or a technically distinct manufacturing process.

Can an excipient supplier obtain regulatory exclusivity for metformin?

An excipient supplier generally does not obtain exclusivity merely by supplying a known excipient. Commercial protection may arise from formulation patents, trade secrets, customer-specific process know-how, proprietary grades, or licensing agreements.

Does metformin have biosimilar competition?

No. Metformin hydrochloride is a small-molecule active ingredient, so competition occurs through generic-drug pathways rather than biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-approval-process-drugs/505b2-approval-process
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs
6. European Medicines Agency. (2018). Guideline on the chemistry of active substances. https://www.ema.europa.eu/